secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAMED PHARMACEUTICALS INC. (ORMP)
CIK:        0001176309
Form:       8-K
Filed at:   2025-01-22T23:59:59+00:00
Accession:  0001213900-25-005212
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oramed extends Scilex note maturity to Dec 2025; receives 3.25M Scilex shares as consideration
--------------------------------------------------------------------------------

- Remaining principal on Tranche A Note is $7.675M; maturity extended from March 21, 2025 to December 31, 2025.
- SCLX JV transferred 3,250,000 shares of Scilex common stock to Oramed as consideration for the extension.
- Note covenants amended: cash sweep definition updated, and Scilex may not increase officer/director compensation while note outstanding.
- Oramed may waive certain prepayments and instead direct prepayment to Tranche B Note holders.
- Extension was a condition for payment deferrals under separate Tranche B Note amendments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1176309/000121390025005212/0001213900-25-005212-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1176309/000121390025005212/ea0228309-8k_oramed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-005212

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer